Literature DB >> 11529935

Interleukin-10 expressed at early tumour sites induces subsequent generation of CD4(+) T-regulatory cells and systemic collapse of antitumour immunity.

N Seo1, S Hayakawa, M Takigawa, Y Tokura.   

Abstract

We investigated the relationship between transforming growth factor-beta (TGF-beta)-secreting T-regulatory (Tr) cells and anti-B16 melanoma immunity, and studied the association of early cytokines expressed at tumour sites with the generation of Tr cells. A large number of CD4(+) Tr cells producing interleukin (IL)-4, IL-10 and TGF-beta accumulated with functionally depressed CD8(+) cytotoxic T lymphocytes (CTLs) at tumour sites on day 20 after subcutaneous (s.c.) inoculation of B16 tumour cells. Tr cells consisted of two populations, which were termed T helper 3 (Th3) and Tr1 cells. B16-infiltrating Tr cells strongly inhibited the generation of B16-specific T helper 1 (Th1) cells in a TGF-beta-dependent manner and were assumed to suppress effective generation of CTLs. In addition, B16 cells markedly progressed in mice transferred adoptively by the cultured B16-infiltrating Tr cells compared with untreated mice. The capacity of these Tr cells to produce TGF-beta was hampered by neutralizing anti-IL-10 and partly anti-IL-4 monoclonal antibodies (mAbs) injected intralesionally during the early development of B16 tumours, and this treatment markedly attenuated B16 growth. Furthermore, a lesional injection of recombinant mouse IL-10 at an early tumour site resulted in the vigorous progression of B16 tumours. These results provide evidence that Tr cells, belonging to the T helper 3/T-regulatory 1 (Th3/Tr1) type, are activated in B16-bearing hosts under the influence of T helper 2 (Th2) cytokines, mainly IL-10 (produced at early tumour lesions), and that this regulatory T-cell population functions as a suppressor of anti-B16 immunity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11529935      PMCID: PMC1783257          DOI: 10.1046/j.1365-2567.2001.01279.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  37 in total

1.  Transforming growth factor-beta-induced inhibition of T cell function. Susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state.

Authors:  T Tada; S Ohzeki; K Utsumi; H Takiuchi; M Muramatsu; X F Li; J Shimizu; H Fujiwara; T Hamaoka
Journal:  J Immunol       Date:  1991-02-01       Impact factor: 5.422

Review 2.  Downregulation of innate and acquired antitumor immunity by bystander gammadelta and alphabeta T lymphocytes with Th2 or Tr1 cytokine profiles.

Authors:  N Seo; Y Tokura
Journal:  J Interferon Cytokine Res       Date:  1999-06       Impact factor: 2.607

3.  Identification and induction of keratinocyte-derived IL-10.

Authors:  A H Enk; S I Katz
Journal:  J Immunol       Date:  1992-07-01       Impact factor: 5.422

4.  Local cytokine production in a murine model of Escherichia coli pyelonephritis.

Authors:  H S Rugo; P O'Hanley; A G Bishop; M K Pearce; J S Abrams; M Howard; A O'Garra
Journal:  J Clin Invest       Date:  1992-03       Impact factor: 14.808

5.  Co-engagement of CD3 with LFA-1 or ICAM-1 adhesion molecules enhances the frequency of activation of single murine CD4+ and CD8+ T cells and induces synthesis of IL-3 and IFN-gamma but not IL-4 or IL-6.

Authors:  E Maraskovsky; A B Troutt; A Kelso
Journal:  Int Immunol       Date:  1992-04       Impact factor: 4.823

Review 6.  Tumor antigens recognized by T lymphocytes.

Authors:  T Boon; J C Cerottini; B Van den Eynde; P van der Bruggen; A Van Pel
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

7.  Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumor-bearing mice and cancer patients.

Authors:  S Kondo; M Asano; K Matsuo; I Ohmori; H Suzuki
Journal:  Biochim Biophys Acta       Date:  1994-03-31

8.  Antigen-specific activation, tolerization, and reactivation of the interleukin 4 pathway in vivo.

Authors:  M Röcken; J Urban; E M Shevach
Journal:  J Exp Med       Date:  1994-06-01       Impact factor: 14.307

9.  Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor.

Authors:  K Inaba; M Inaba; N Romani; H Aya; M Deguchi; S Ikehara; S Muramatsu; R M Steinman
Journal:  J Exp Med       Date:  1992-12-01       Impact factor: 14.307

10.  In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression.

Authors:  H I Levitsky; A Lazenby; R J Hayashi; D M Pardoll
Journal:  J Exp Med       Date:  1994-04-01       Impact factor: 14.307

View more
  54 in total

Review 1.  The lymphatic system and pancreatic cancer.

Authors:  Darci M Fink; Maria M Steele; Michael A Hollingsworth
Journal:  Cancer Lett       Date:  2015-12-29       Impact factor: 8.679

2.  Low molecular weight fraction secreted by SKOV3 cells expands peripheral CD4+CD25+ regulatory T cells and enhances their suppressive capacity.

Authors:  Xiao Li; Xiaoyun Wan; Yuyan Mao; Weiguo Lu; Xing Xie
Journal:  Med Oncol       Date:  2009-06-17       Impact factor: 3.064

3.  Potential effect of tumor-specific Treg-targeted antibodies in the treatment of human cancers: A bioinformatics analysis.

Authors:  Luigi Cari; Giuseppe Nocentini; Graziella Migliorati; Carlo Riccardi
Journal:  Oncoimmunology       Date:  2017-11-09       Impact factor: 8.110

4.  Vaccine-induced but not tumor-derived Interleukin-10 dictates the efficacy of Interleukin-10 blockade in therapeutic vaccination.

Authors:  Diana Llopiz; Fernando Aranda; Nancy Díaz-Valdés; Marta Ruiz; Stefany Infante; Virginia Belsúe; Juan José Lasarte; Pablo Sarobe
Journal:  Oncoimmunology       Date:  2015-08-12       Impact factor: 8.110

5.  Expression of a "self-"antigen by human tumor cells enhances tumor antigen-specific CD4(+) T-cell function.

Authors:  Christopher E Touloukian; Wolfgang W Leitner; Paul F Robbins; Yong F Li; Xiaoqiang Kang; Rejean Lapointe; Patrick Hwu; Steven A Rosenberg; Nicholas P Restifo
Journal:  Cancer Res       Date:  2002-09-15       Impact factor: 12.701

6.  Susceptibility of T cell receptor-alpha chain knock-out mice to ultraviolet B light and fluorouracil: a novel model for drug-induced cutaneous lupus erythematosus.

Authors:  T Yoshimasu; T Nishide; N Seo; A Hiroi; T Ohtani; K Uede; F Furukawa
Journal:  Clin Exp Immunol       Date:  2004-05       Impact factor: 4.330

7.  An Open-Label Study of the Safety and Efficacy of Tag-7 Gene-Modified Tumor Cells-Based Vaccine in Patients with Locally Advanced or Metastatic Malignant Melanoma or Renal Cell Cancer.

Authors:  Aleksei Viktorovich Novik; Anna Borisovna Danilova; Maksim Ivanovich Sluzhev; Tatiana Leonidovna Nehaeva; Sergei Sergeevich Larin; Dmitry Viktorovich Girdyuk; Svetlana Anatolevna Protsenko; Anna Igorevna Semenova; Aleksei Olegovich Danilov; Vladimir Mikhailovich Moiseyenko; Georgii Pavlovich Georgiev; Irina Aleksandrovna Baldueva
Journal:  Oncologist       Date:  2020-04-07

8.  Normal tissue depresses while tumor tissue enhances human T cell responses in vivo to a novel self/tumor melanoma antigen, OA1.

Authors:  Christopher E Touloukian; Wolfgang W Leitner; Rhonda E Schnur; Paul F Robbins; Yong Li; Scott Southwood; Alessandro Sette; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Immunol       Date:  2003-02-01       Impact factor: 5.422

9.  Stat6 signaling suppresses VLA-4 expression by CD8+ T cells and limits their ability to infiltrate tumor lesions in vivo.

Authors:  Kotaro Sasaki; Xi Zhao; Angela D Pardee; Ryo Ueda; Mitsugu Fujita; Sarita Sehra; Mark H Kaplan; Lawrence P Kane; Hideho Okada; Walter J Storkus
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

10.  Intratumoral CD4+ T lymphodepletion sensitizes poorly immunogenic melanomas to immunotherapy with an OX40 agonist.

Authors:  Susumu Fujiwara; Hiroshi Nagai; Noriko Shimoura; Shuntaro Oniki; Takayuki Yoshimoto; Chikako Nishigori
Journal:  J Invest Dermatol       Date:  2014-01-27       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.